NurExone Biologic Inc. (TSXV:NRX) has been making significant strides in the field of exosome-based therapies. And just last month the company announced the acquisition of a US master cell bank, followed by the formation of Exo-Top Inc.
Lyndsay Malchuk from Stockhouse Publishing sat down with CEO, Dr. Lior Shaltiel to converse about all of these topics and more.
The following is a transcription of the above video, and The Market Online has edited it for clarity.
Lyndsay: NurExone has been making some significant waves in the biotech as well as the regenerative medicine sector. Walk us through a little bit about the company and also the innovative therapies that you’re developing to work with central nervous system regeneration.
Lior: We are a company that focuses on CNS (central nerve system) regeneration. How we do it, we do it with exosomes. Exosomes are tiny vesicles secreted from cells.
It’s the ultimate drug delivery system in our opinion.
We are using it as a drug delivery system with our special siRNA in order to promote the regeneration of neurons. How we do it and in which setting? We start in a spinal cord injury in 2024.
We also show efficacy in optic nerve damage and in glaucoma.
It’s already the second indication and the mechanism is quite clear. We want to reduce a certain protein called PTEN and this promotes exosome growth. Then reconnectivity of the nerves and functional recovery.
Lyndsay: You mentioned in January you secured a US master cell bank and then in February you actually announced the formation of Exo-Top. Break down the strategic rationale behind that move and how it positions the company for future growth?
Lior: It’s an excellent point. We are going very fast with the news and this story will continue to be revealed with time.
So, step by step, we first of all secured the master cell bank because we need the cell source, it’s how we produce exosome from cells. We want the best cells that we can have.
This is a fully characterized GMP bone marrow master cell bank from humans. We use it for our exosome and those cells, secrete exosomes.
We collect the exosomes and then modify them to have a loading of our siRNA. So, we secure the best cell source for us.
As I said, it’s fully characterized. It can have all the regulatory checks that we need in order to submit it for our IND.
What is a master cell bank? I will give you analogy. We need a glass of milk, but the master cell bank is so huge, it’s like the cow shed. And so that you can produce revenue, you established a US subsidiary. And this subsidiary would be responsible to produce cells (your glass of milk in this analogy) and exosomes in order, first of all for our consumption and second, for third parties as a B2B business.
Lyndsay: On top of this progress, NurExone has been named as part of the TSX Venture top 50 of 2025.
That is a notable achievement on top of everything else. So, congratulations to that.
Now tell us about the key milestones and the performance metrics that you believe got you that recognition and how does it position the company right now.
Lior: It’s a huge achievement, especially because we are young. We are just less than three years in the market.
This we achieved after two years.
It’s based on data that the TMX had in 2024. So, it was amazing years for us.
The market cap growth, more than 100% and liquidity went up. So, I’m very happy with that.
It’s not magic, it’s a lot of hard work and behind this hard work is the team of NurExone, the research team, the financial team, the Directors that lead us to this achievement.
NurExone is a young company with a fully dedicated for the story. And there is a huge motivation to succeed in Canada.
As we also said in the press release, also in the US soon.
Lyndsay: With all of these developments, how do you see NurExone’s competitive, evolving position in the exosome supply market?
Lior: This returns to the other question that you asked. When you have a good source of cells and you have sufficient cells that regulatory wise have ticked all the boxes, and the FDA’s is content from that you can supply the demand of exosomes on the world scale. This is not only for NurExone’s demand for research and development, it’s also for the future of the drug.
It’s also for other indications for other territories. For example, in cosmetics, in other industries that maybe are less under a full regulation. And NurExone can be a key point for this market.
Lyndsay: So, are those the things that differentiate you from all the other people in the market, or are there even more things that you’re working on?
Lior: We are, first of all, a pharmaceutical company. Yes, we are going to the IND. We are going to a clinical state company.
Second, because we have the source of cells, our mission is to supply the demand of exosomes in different fields at the highest standards. However, the focus ,first of all, is on our drug. And that’s what we do.
Lyndsay: All of these are some major catalysts that have happened already. And congratulations to all that. What should investors be looking at in the coming quarters?
Lior: Continue to follow up on our news. You can do it in a public arena like Stockhouse, like in our social media activity, and our next press release.
The story of Exo-Top is going to be revealed step by step. And this will give the investors a clearer pathway to where we are going.
Our last press release talked about our intention to go to the US market. This of course will be part of our aim in 2025.
So, there are a lot of milestones on the way and it will be a very interesting year for us.
You can find NurExone Biologic Inc. on the Venture under the ticker symbol NRX and their website is nurexone.com for more information.
Company shares last traded at $0.570
Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
